🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes

Recruitingn/aAges any - anyAllAzienda Socio Sanitaria Territoriale degli Spedal…
NCT03058588 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease will be done. The screening will be performed on affected and unaffected family members, in order to outline new pedigrees that either validate previous findings or constitute novel discoveries.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: Any patient with acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) with: 1. a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies 2. a first- or second-degree relative with Lymphoproliferative neoplasms 3. or with clinical features that resemble one of the familial MDS/AML predisposition syndromes: * History of thrombocytopenia and/or a clinical bleeding propensity (as in RUNX1, ANKRD26 or ETV6 germline mutations) * Abnormal nails or skin pigmentation, oral leukoplakia, idiopathic pulmonary fibrosis, unexplained liver disease (as in TERT and TERC germline mutations) * Lymphedema, atypical infections, immune deficiencies (as in GATA2 germline mutations) Exclusion Criteria: 1. any diagnosis other than acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS); 2. acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) without a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies or without a first- or second-degree relative with Lymphoproliferative neoplasms or with clinical features that resemble one of the familial MDS/AML predisposition syndromes; 3. unability to sign the informed consent
💊

What it tests

  • Analysis with molecular biology
📍

Where

1 site
Chair of Hematology and Bone marrow Transplant Unit
Brescia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy